Abstract
Pentraxins are a superfamily of fluid-phase protein acting as pattern recognition molecules (PRMs) of the immune system, which seems to have a key role both in inflammation and cancer. Pentraxin 3 (PTX3), the prototype of long pentraxins, plays a multifunctional role ranging between resistance against pathogens, opsonic activity via Fc receptor, modulation of inflammatory states, and clearance of apoptotic cells. Interestingly, PTX3 has the ability to influence the complement system (CS) modulation via its interaction with some key factors of the complement cascade. PTX3 sustains carcinogenesis, enriching tumor microenvironment (TEM) with pro-inflammatory molecules promoting neoplastic cell proliferation, tumor growth, angiogenesis, and metastasis spreading. The pleiotropic role of PTX3 in cancer pathogenesis is likely to be context dependent. Of note, PTX3 shows an uncertain role in cancer development by also acting as a tumor suppressor factor via inducing dysregulation of mitogenic pathways, alteration of proliferative signalling, and inhibition of neovascularization. This chapter aims to elucidate the ambivalent role of PTX3 in carcinogenesis.
References
Choi B, Lee EJ, Shin MK et al (2016) Upregulation of brain-derived neurotrophic factor in advanced gastric cancer contributes to bone metastatic ostolysis by inducing long pentraxin 3. Oncotarget 7:55506–55517
Bastrup-Birk S, Skjoedt MO, Munthe-Fog L et al (2013) Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 8:e73119
Bonavita E, Gentile S, Rubino M et al (2015) PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer. Cell 160:700–714
Bottazzi B, Inforzato A, Messa M et al (2016) The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol 64:1416–1427
Braunschweig A, Józsi M (2011) Human Pentraxin 3 binds to the complement regulator C4b-binding protein. PLoS One 6:e23991
Brunetta E, Folci M, Bottazzi B et al (2021) Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol 22:19–24
Bussolati B, Peri G, Salvidio G et al (2003) The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 170:1466–1472
Chan SH, Tsai JP, Shen CJ et al (2017) Oleate-induced PTX3 promotes head and neck squamous cell carcinoma, metastasis through the up-regulation of vimentin. Oncotarget 8:41364–41378
Chang WC, Wu SL, Huang WC et al (2015) PTX3 gene activation in EGF-induced head and neck cancel cell metastasis. Oncotarget 6:7741–7757
Chang X, Li D, Liu C et al (2021) Pentraxin 3 is a diagnostic and prognostic marker for ovarian epithelial cancer patients based on comprehensive bioinformatics and experiments. Cancer Cell Int 21(1):1–13
Choi B, Lee EJ, Park YS et al (2015) Elevated Pentraxin-3 silencing suppress gastric cancer-related inflammation by inhibiting chemotactic migration of macrophages. Anticancer Res 35:2663–2668
Daigo K, Hamakubo T (2012) Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps. Front Immunol 3:378
Daigo K, Inforzato A, Barajon I et al (2016) Pentraxins in the activation and regulation of innate immunity. Immunol Rev 274:202–217
Deban L, Bottazzi B, Garlanda C et al (2009) Pentraxins: multifunctional proteins at the interface of innate immunity and inflammation. Biofactors 35:138–145
Di Virgilio F (2015) A commentary on “PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer”. Front Oncol 5:118
Diamandis EP, Goodglick L, Planque C et al (2011) Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 17:2395–2399
Doni A, Stravalaci M, Inforzato A et al (2019) The long pentraxin PTX3 as a link between innate immunity, tissue remodeling, and cancer. Front Immunol 10:1–13
Falagario UG, Busetto GM, Netti GS et al (2021) Prospective validation of Pentraxin-3 as a novel serum biomarker to predict the risk of prostate cancer in patients scheduled for prostate biopsy. Cancers 13:1611
Fazzini F, Peri G, Doni A et al (2001) PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 44:2841–2850
Ferlay J, Shin HR, Bray F et al (2017) Estimates of worldwide burden of cancer in 2008: GLOBOCAN. J Cancer 12:2893–2917
Finke J, Kierstead LS, Ranieri E et al (2000) Immunologic response to RCC. In: Renal cell carcinoma, molecular biology, immunology and clinical management. Humana Press, Inc., Totowa, pp 39–62
Garlanda C, Bottazzi B, Magrini E et al (2018) PTX3, a humoral pattern recognition molecule, in innate immunity, tissue repair, and cancer. Physiol Rev 98:623–639
Giacomini A, Ghedini GC, Presta M et al (2018) Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta Rev Cancer 1869:53–63
Granucci F, Bottazzi B, Garlanda C et al (2019) Editorial: the role of pentraxins: from inflammation, tissue repair and immunity to biomarkers. Front Immunol 10:2817
Han B, Mura M, Andrade CF et al (2005) TNFalpha-induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol 175:8303–8311
Infante M, Allavena P, Garlanda C et al (2016) Prognostic and diagnostic potential of local and circulating levels of pentraxins 3 in lung cancer patients. Int J Cancer 138:983–991
Inforzato A, Bottazzi B, Garlanda C et al (2012) Pentraxins in humoral innate immunity. Adv Exp Med Biol 946:1–20
Inforzato A, Reading PC, Barbati E et al (2013) The “sweet” side of a long pentraxin: how glycosylation affects PTX3 functions in innate immunity and inflammation. Front Immunol 0:407
Jaillon S, Peri G, Delneste Y et al (2007) The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 204:793–804
Karczmarski J, Rubel T, Mikula M et al (2013) Pre-analytical-relatet variability influencing serum peptide profiles demonstrated in a mass spectrometry-based search for colorectal and prostate cancer biomarkers. Acta Biochim Pol 60:417–425
Kim M, Kwon JH, Bae YK et al (2020) Soluble PTX3 of human umbilical cord blood-derived mesenchymal stem cells attenuates hyperoxic lung injury by activating macrophage polarization in neonatal rat model. Stem Cells Int 2020:1802976
Korniluk A, Koper O, Kemona H et al (2017) From inflammation to cancer review. Ir J Med Sci 186:57–62
Li Y, Song X, Niu J et al (2021) Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer. Arch Biochem Biophys 701:108818
Liu S, Qu X, Liu F et al (2014) Pentraxin 3 as a prognostic biomarker in patients with systemic inflammation or infection. Mediat Inflamm 2014:421429
Loberg RD, Day LL, Dunn R et al (2006) Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8:69–78
Ma YJ, Garred P (2018) Pentraxins in complement activation and regulation. Front Immunol 9:3046
Magrini E, Mantovani A, Garlanda C et al (2016) The dual complexity of PTX3 in health and disease: a balancing act? Trends Mol Med 22:497–510
Manning ML, Williams SA, Jelinek CA et al (2013) Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. J Immunol 190:2567–2574
Mantovani A, Valentino S, Gentile S et al (2013) The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci 1285:1–14
Moalli F, Jaillon S, Inforzato A et al (2011) Pathogen recognition by the long pentraxin PTX3. J Biomed Biotechnol 2011:830421
Nauta AJ, de Haij S, Bottazzi B et al (2005) Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 67:543–553
Netti GS, Lucarelli G, Spadaccino F et al (2020) PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma. Aging (Albany NY) 12:7585–7602
Netti GS, Franzin R, Stasi A, Spadaccino F, Dello Strologo A, Infante B, Gesualdo L, Castellano G, Ranieri E, Stallone G (2021) Role of complement in regulating inflammation processes in renal and prostate cancers. Cell 10:2426
Porte R, Davoudian S, Asgari F et al (2019) The long pentraxin PTX3 as a humoral innate immunity functional player and biomarker of infections and sepsis. Front Immunol 10:1–11
Rathore M, Girard C, Ohanna M et al (2019) Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene 38:5873–5889
Ravizza T, Moneta D, Bottazzi B et al (2001) Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 105:43–53
Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10:63–89
Revel M, Daugan MV, Sautés-Fridman C et al (2020) Complement system: promoter or suppressor of cancer progression? Antibodies (Basel) 9:57
Ronca R, Giacomini A, Di Salle E et al (2015) Long-Pentraxine 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell 28:225–239
Roumenina LT, Daugan MV, Petitprez F et al (2019) Context-dependent roles of complement in cancer. Nat Rev Cancer 19:698–715
Rubino M, Kunderfranco P, Basso G et al (2017) Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Onco Targets Ther 6:1–12
Rutkowski MJ, Sughrue ME, Kane AJ et al (2010) Cancer and the complement cascade. Mol Cancer Res 8:1453–1465
Schmid MC, Varner JA (2007) Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 250:1–8
Schröder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328
Shiraki A, Kotooka N, Komoda H et al (2016) Pentraxin-3 regulates the inflammatory activity of macrophages. Biochem Biophys Rep 5:290–295
Song T, Wang C, Guo C et al (2018) Pentraxin 3 overexpression accelerated tumor metastasis and indicated poor prognosis in hepatocellular carcinoma via driving epithelial-mesenchymal transition. J Cancer 9:2650–2658
Spadaccino F, Netti GS, Rocchetti MT et al (2020) Diagnostic and prognostic markers of renal cell carcinoma. G Ital Nefrol 37:2012–2020
Stallone G, Cormio L, Netti GS et al (2014) Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res 74:4230–4238
Stallone G, Netti GS, Cormio L et al (2020) Modulation of complement activation by pentraxin-3 in prostate cancer. Sci Rep 10:18400
Thomas C, Henry W, Cuiffo BG et al (2017) Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Sci Signal 10:eaah4674
Tung JN, Ko CP, Yang SF et al (2016) Inhibition of pentraxin 3 in glioma cells impairs proliferation and invasion in vitro and in vivo. J Neuro-Oncol 129:201–209
Uusitalo-Seppälä R, Huttunen R, Aittoniemi J et al (2013) Pentraxin 3 (PTX3) is associated with severe sepsis and fatal disease in emergency room patients with suspected infection: a prospective cohort study. PLoS One 8:e53661
Vega CA, Mommert M, Boccard M et al (2019) Source of circulating pentraxin 3 in septic shock patients. Front Immunol 9:3048
Wang Z, Wang X, Zou H et al (2020) The basic characteristics of the pentraxin family and their functions in tumor progression. Front Immunol 11:1–16
Xu C, Jung M, Burkhardt M, Stephan C, Schnorr D, Loening S, Jung K, Dietel M, Kristiansen G et al (2005) Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy. Prostate 62:224–232
Ying TH, Lee CH, Chiou HL et al (2016) Knockdown of Pentraxin 3 suppresses tumorigenicity and metastasis of human cervical cancer cells. Sci Rep 6:29385
Zhou W, Marsh JE, Sacks SH et al (2001) Intrarenal synthesis of complement. Kidney Int 59:1227–1235
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Catalano, V., Spadaccino, F., Gigante, M., Netti, G.S., Ranieri, E. (2022). Long Pentraxins and Cancer: A Complex Role Between Immunity and Inflammation. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_29-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_29-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences